Status:
UNKNOWN
Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors
Lead Sponsor:
Samsung Medical Center
Conditions:
Neuroblastoma
Ewing Sarcoma
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
Brief Summary
To evaluate feasibility and efficacy of haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transpl...
Detailed Description
HaploSCT following reduced-intensity conditioning (RIC) regimen will be performed in patients with high-risk solid tumors. Both parents will be evaluated for their KIR genotype and phenotype and the o...
Eligibility Criteria
Inclusion
- age \< 21 years old
- Patients with high-risk solid tumors who failed prior HDCT/autoSCT
- Patients with a suitable haploidentical donor
- High-risk solid tumors include high-risk neuroblastoma, metastatic or relapsed Ewing sarcoma, relapsed osteosarcoma, high-risk brain tumors, relapsed germ cell tumors, relapsed soft tissue sarcoma, relapsed rhabdomyosarcoma, and etc.
- stable disease with salvage chemotherapy after relapse
Exclusion
- organ dysfunction(NCI common toxicity criteria grade \> 2)
- progression of disease despite salvage chemotherapy
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2019
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01807468
Start Date
May 1 2013
End Date
June 1 2019
Last Update
September 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710